Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the month of February 2023. The report discloses regulatory compliance actions taken under Australian law regarding changes in director interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly informational regarding corporate governance and does not contain financial performance data.
Material Changes
On February 23, 2023, the Company lodged Change in Director's Interest Notices with the Australian Securities Exchange (ASX) on behalf of:
- Dr. Errol De Souza
- Dr. Spyros Papapetropoulos
These notices disclose changes in their interests in the Company's securities and contracts.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to transmit the attached director interest notices.
Investor Verification Checklist
- Verify the specific nature and magnitude of the interest changes for Dr. De Souza and Dr. Papapetropoulos in the attached Exhibits 99.1 and 99.2.
- Confirm the company name is Bionomics Limited, as the metadata reference to Neuphoria Therapeutics Inc. appears to be an error in the request context.
- Review the full Appendix 3Y notices for any potential conflicts of interest or insider trading implications.